a 1 Fairleigh Dickinson University, School of Pharmacy, 230 Park Avenue, M-SP1-01, Florham Park, NJ 07901, USA.
b 2 Long Island University Arnold & Marie Schwartz College of Pharmacy and Health Sciences, 450 Clarkson Avenue Box 36, Brooklyn, NY 11203, USA.
Expert Rev Anti Infect Ther. 2015;13(10):1195-212. doi: 10.1586/14787210.2015.1075393. Epub 2015 Aug 9.
Integrase strand transfer inhibitors (INSTIs) are oral antiretroviral agents used against HIV infection. There are three agents available, including raltegravir, elvitegravir and dolutegravir, some of which are available as combination medications with other antiretroviral drugs. The efficacy and safety of INSTIs in treatment-naïve and experienced HIV-infected patients have been established by multiple studies. Based on the current practice guidelines, INSTI-based regimens are considered as one of the first-line therapies for treatment-naïve HIV-infected patients. There are new INSTIs in development to improve the resistance profile and to decrease the frequency of drug administration.
整合酶链转移抑制剂(INSTIs)是用于抗 HIV 感染的口服抗逆转录病毒药物。目前有三种药物可用,包括雷特格韦、艾维雷格韦和多替拉韦,其中一些与其他抗逆转录病毒药物联合使用。多项研究已经证实了 INSTIs 在初治和经治 HIV 感染患者中的疗效和安全性。根据当前的实践指南,基于 INSTI 的方案被认为是初治 HIV 感染患者的一线治疗方案之一。目前正在开发新的 INSTIs,以改善耐药谱并减少药物给药频率。